Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro.

Literature DB >> 12604560

Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro.

Eugene Lin¹, Ronald J Stanek, Maurice A Mufson.

Abstract

We investigated a possible synergistic effect of a macrolide and beta-lactams against Streptococcus pneumoniae strains with different resistance profiles. Checkerboard and time-kill assays of erythromycin combined with penicillin or cefotaxime essentially showed indifference, suggesting that these antibiotics in combinations in vitro act substantially as individuals in their activity against S. pneumoniae.

Entities: Chemical Species

Mesh：

Substances：

Year: 2003 PMID： 12604560 PMCID： PMC149295 DOI： 10.1128/AAC.47.3.1151-1153.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

1. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.

Authors: H K Johansen; T G Jensen; R B Dessau; B Lundgren; N Frimodt-Moller
Journal: J Antimicrob Chemother Date: 2000-12 Impact factor: 5.790

2. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

Authors: M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu
Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405

Review 3. Pneumococcal macrolide resistance--myth or reality?

Authors: G W Amsden
Journal: J Antimicrob Chemother Date: 1999-07 Impact factor: 5.790

4. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.

Authors: J G Bartlett; R F Breiman; L A Mandell; T M File
Journal: Clin Infect Dis Date: 1998-04 Impact factor: 9.079

5. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods.

Authors: S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1996-09 Impact factor: 5.191

6. Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci.

Authors: M E Gross; K P Giron; J D Septimus; E O Mason; D M Musher
Journal: Antimicrob Agents Chemother Date: 1995-05 Impact factor: 5.191

7. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association.

Authors: M S Niederman; J B Bass; G D Campbell; A M Fein; R F Grossman; L A Mandell; T J Marrie; G A Sarosi; A Torres; V L Yu
Journal: Am Rev Respir Dis Date: 1993-11

8. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

Authors: G W Waterer; G W Somes; R G Wunderink
Journal: Arch Intern Med Date: 2001 Aug 13-27

9. Emergence of penicillin-resistant invasive pneumococci in a single American community.

Authors: R J Stanek; M A Mufson
Journal: Am J Med Sci Date: 1995-10 Impact factor: 2.378

10. Antibacterial profile of flurithromycin, a new macrolide.

Authors: D Saverino; E A Debbia; A Pesce; A M Lepore; G C Schito
Journal: J Antimicrob Chemother Date: 1992-09 Impact factor: 5.790

8 in total

1. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia.

Authors: R Dwyer; A Ortqvist; E Aufwerber; B Henriques Normark; T J Marrie; M A Mufson; A Torres; M A Woodhead; M Alenius; M Kalin
Journal: Eur J Clin Microbiol Infect Dis Date: 2006-08 Impact factor: 3.267

2. Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia.

Authors: Daisuke Yoshioka; Chiaki Kajiwara; Yoshikazu Ishii; Kenji Umeki; Kazufumi Hiramatsu; Jun-Ichi Kadota; Kazuhiro Tateda
Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191

Review 3. Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors: Soichiro Kanoh; Bruce K Rubin
Journal: Clin Microbiol Rev Date: 2010-07 Impact factor: 26.132

4. Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens.

Authors: Hyeri Seok; Jae-Hoon Ko; Kyong Ran Peck; Ji-Yeon Kim; Ji Hye Lee; Ga Eun Park; Sun Young Cho; Cheol-In Kang; Nam Yong Lee; Doo Ryeon Chung
Journal: Pneumonia (Nathan) Date: 2019-06-05

Review 8. An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Authors: Anand Kumar
Journal: Virulence Date: 2013-11-01 Impact factor: 5.882